Argatroban drug interactions: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
====7.1 Heparin==== | ====7.1 Heparin==== | ||
If argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparin's effect on the aPTT to decrease prior to initiation of argatroban therapy. | If argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparin's effect on the [[aPTT]] to decrease prior to initiation of argatroban therapy. | ||
====7.2 Oral Anticoagulant Agents==== | ====7.2 Oral Anticoagulant Agents==== | ||
Pharmacokinetic drug-drug interactions between argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of argatroban and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5) and Clinical Pharmacology (12.2)]. | Pharmacokinetic drug-drug interactions between argatroban and [[warfarin]] (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of argatroban and [[warfarin]] (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the [[prothrombin time]] (PT) and [[International Normalized Ratio]] (INR) [see Dosage and Administration (2.5) and Clinical Pharmacology (12.2)]. | ||
====7.3 Aspirin/Acetaminophen==== | ====7.3 Aspirin/Acetaminophen==== | ||
No drug-drug interactions have been demonstrated between argatroban and concomitantly administered aspirin or acetaminophen [see Clinical Pharmacology (12.3)]. | No drug-drug interactions have been demonstrated between argatroban and concomitantly administered [[aspirin]] or [[acetaminophen]] [see Clinical Pharmacology (12.3)]. | ||
====7.4 Thrombolytic Agents==== | ====7.4 Thrombolytic Agents==== | ||
| Line 22: | Line 22: | ||
====7.5 Glycoprotein IIb/IIIa Antagonists==== | ====7.5 Glycoprotein IIb/IIIa Antagonists==== | ||
The safety and effectiveness of argatroban with glycoprotein IIb/IIIa antagonists have not been established.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher = | date = | accessdate = }}</ref> | The safety and effectiveness of argatroban with glycoprotein [[IIb/IIIa]] antagonists have not been established.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher = | date = | accessdate = }}</ref> | ||
==Reference== | ==Reference== | ||
Revision as of 12:53, 6 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Drug Interactions
7.1 Heparin
If argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparin's effect on the aPTT to decrease prior to initiation of argatroban therapy.
7.2 Oral Anticoagulant Agents
Pharmacokinetic drug-drug interactions between argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of argatroban and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5) and Clinical Pharmacology (12.2)].
7.3 Aspirin/Acetaminophen
No drug-drug interactions have been demonstrated between argatroban and concomitantly administered aspirin or acetaminophen [see Clinical Pharmacology (12.3)].
7.4 Thrombolytic Agents
The safety and effectiveness of argatroban with thrombolytic agents have not been established [see Adverse Reactions (6.3)].
7.5 Glycoprotein IIb/IIIa Antagonists
The safety and effectiveness of argatroban with glycoprotein IIb/IIIa antagonists have not been established.[1]
Reference
Adapted from the FDA Package Insert.